Tenofovir and kidney health in chronic hepatitis B
Treatments studied
Part of Infections, Kidney & urinary clinical trials.
This study examines how long-term use of the hepatitis B medicine Tenofovir (TDF) affects kidney function. It may help doctors understand how to better monitor and protect your kidneys while treating hepatitis B.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with chronic hepatitis B (HBV).
- You have been taking Tenofovir Disoproxil Fumarate (TDF) for more than 5 years.
- You do not have other chronic liver diseases.
- You do not have chronic kidney disease (CKD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how long-term use of the hepatitis B medicine Tenofovir (TDF) affects bone density. It may help you understand potential bone health risks if you've been taking TDF for over five years.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This study tests if switching your current hepatitis B antiviral to Tenofovir Alafenamide (TAF) keeps your new liver working well with fewer side effects. It is for people who had a liver transplant due to hepatitis B and have stable liver function for at least a year.
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
This study tests whether the medicine tenofovir disoproxil can help prevent passing hepatitis B from mother to baby during pregnancy. It is for pregnant women with an active hepatitis B infection who are early in their pregnancy (less than 24 weeks).
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
Hear when a new Chronic HBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.